ELITE PHARMS INC - ELTP STOCK NEWS

Elite Pharmaceuticals (OTCQB:ELTP) announced its financial results for the second quarter of fiscal year 2023, ending September 30, 2022, with consolidated revenues reaching $16.3 million, a 4% increase year-over-year. This growth is primarily due to revenues from generic Adderall. However, operating profits fell to $2.1 million, a decrease of $0.28 million compared to the previous year, while net income was reported at $1.82 million. A conference call is scheduled for November 15, 2022, to discuss results and updates.

Elite Pharmaceuticals (OTCQB:ELTP) announced that it will release its financial results for the second quarter of the 2023 fiscal year, ending September 30, 2022, on November 14, 2022. A live conference call is scheduled for November 15, 2022, at 11:30 AM EST, where management will discuss the financial and operational outcomes as well as provide a business update. Investors can submit questions via email prior to the call. Elite focuses on developing and manufacturing niche generic products, with a registered facility in Northvale, NJ.

Elite Pharmaceuticals reported positive results from pivotal bioequivalence studies for a generic extended-release drug in the dopamine agonist class. The studies confirmed that the generic product is bioequivalent to its branded counterpart. IQVIA reported an annual market revenue of $12 million for this product as of August 2022. Elite will file an Abbreviated New Drug Application with the FDA, supporting future growth potential. The company specializes in niche generic products and operates a cGMP and DEA registered facility in Northvale, NJ.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported its financial results for the first quarter of fiscal year 2023 ending June 30, 2022. Consolidated revenues increased by 9% to $7.7 million, driven by sales of generic Adderall products. Operating profits rose to $1.0 million, marking a $0.06 million increase from the prior year. Net income reached $0.31 million. A conference call is scheduled for August 16, 2022, to discuss these results and answer shareholder questions.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported significant financial results for the fiscal year ended March 31, 2022. Consolidated revenues grew by 27% to $32.3 million, largely driven by sales of generic Adderall and Naltrexone Tablets. Operating profits increased to $5.1 million, up $3.0 million year-over-year, while net income reached $8.9 million. The company is set to discuss these results in a conference call scheduled for June 30, 2022, at 11:30 AM EDT. For more details, stakeholders are encouraged to submit questions ahead of the call.

Elite Pharmaceuticals has received FDA approval for its generic version of Sabril (Vigabatrin USP) 500 mg powder for solution. This antiepileptic drug is indicated for refractory complex partial seizures, targeting patients with inadequate responses to alternative treatments. Lannett Company holds the exclusive marketing rights in the U.S. and territories, while Elite will manufacture and package the product. The collaboration entails shared profits from product net sales, enhancing Elite's market position in the specialty pharmaceutical sector.

Elite Pharmaceuticals (OTCQB:ELTP) announced it will release its 2022 year-end financial results on June 29, 2022. Following this, a live conference call will be held on June 30, 2022, at 11:30 AM EDT, where management will discuss financial and operational results. Stockholders are encouraged to submit questions prior to the call. Elite Pharmaceuticals specializes in the development of niche generic products and operates a cGMP and DEA registered facility for manufacturing.

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced the appointment of Robert Chen, CPA/MPA, as its new Chief Financial Officer (CFO), effective May 16, 2022, succeeding Marc Bregman. Chen, with over 20 years of experience in financial leadership within the life sciences sector, previously held significant roles at notable firms including KBP Biosciences and Novartis. His expertise in financial reporting and operational management is expected to strengthen Elite's executive team and contribute positively to its financial operations.

Elite Pharmaceuticals (OTCQB:ELTP) announced FDA approval for doxycycline hyclate 100 mg tablets, an antibiotic targeting various bacterial infections. This approval was achieved in collaboration with Praxgen Pharmaceuticals. The company specializes in niche generic products and operates a registered facility in Northvale, NJ. The approval could enhance Elite's market presence and revenue potential in the competitive pharmaceutical space.